Structure and function of OprD protein in Pseudomonas aeruginosa: From antibiotic resistance to novel therapies

International Journal of Medical Microbiology

Volumn 302, Issue 2, 2012, Pages 63-68

  Li, Hui ^a   Luo, Yi Feng ^a   Williams, Bryan J ^b   Blackwell, Timothy S ^c,d   Xie, Can Mao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Carbapenem; OprD; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; ARGININE; ASPARTIC ACID; BACTERIAL PROTEIN; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEFTOLOZANE; CHLORAMPHENICOL; CIPROFLOXACIN; DORIPENEM; E 1010; HEAVY METAL EFFLUX PUMP CZCCBA; HISTIDINE; IMIPENEM; LEVOFLOXACIN; LYSINE; MEROPENEM; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN F; OUTER MEMBRANE PROTEIN OPRD; PENICILLIN BINDING PROTEIN; PEPTIDE P2 15; PEPTIDE P2 27; PROTEIN CZCR; PROTEIN CZCS; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; TETRACYCLINE; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BINDING SITE; CELL MEMBRANE PERMEABILITY; DOWN REGULATION; DRUG MEGADOSE; DRUG PENETRATION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DOMAIN; PSEUDOMONAS AERUGINOSA; SHORT SURVEY; UPREGULATION; URINARY TRACT INFECTION;

AMINO ACIDS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; IMIPENEM; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84858117285     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2011.10.001     Document Type: Short Survey

References (60)

1. Ballestero S., Fernández-Rodríguez A., Villaverde R., Escobar H., Pérez-Díaz J.C., Baquero F. Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients. J. Antimicrob. Chemother. 1996, 38:39-45.
2. Barth A.L., Pitt T.L. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa. J. Med. Microbiol. 1996, 45:110-119.
3. Biswas S., Mohammad M.M., Patel D.R., Movileanu L., van den Berg B. Structural insight into OprD substrate specificity. Nat. Struct. Mol. Biol. 2007, 14:1108-1109.
4. Borgianni L., Prandi S., Salden L., Santella G., Hanson N.D., Rossolini G.M., Docquier J.D. Genetic context and biochemical characterization of IMP-18 metallo-beta lactamase identified in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 2011, 55:140-145.
5. Büscher K.H., Cullmann W., Dick W., Opferkuch W. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob. Agents Chemother. 1987, 31:703-708.
6. Caille O., Rossier C., Perron K. A copper-activated two-component system interacts with zinc and imipenem resistance in Pseudomonas aeruginosa. J. Bacteriol. 2007, 189:4561-4568.
7. Chevalier S., Bodilis J., Jaouen T., Barray S., Feuilloley M.G.J., Orange N. Sequence diversity of the OprD protein of environmental Pseudomonas strains. Environ. Microbiol. 2007, 9:824-835.
8. Conejo M.C., García I., Martínez-Martínez L., Picabea L., Pascual á. Zinc eluted from siliconized latex urinary catheters decreases OprD expression, causing carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2003, 47:2313-2315.
9. Epp S.F., Köhler T., Plésiat P., Michéa-Hamzehpour M., Frey J., Pechère J.C. C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem. Antimicrob. Agents Chemother. 2001, 45:1780-1787.
10. Farra A., Islam S., Strålfors A., Sörberg M., Wretlind B. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomona aeruginosa to imipenem and meropenem. Int. J. Antimicrob. Agents 2008, 31:427-433.
11. Fukuoka T., Masuda N., Takenouchi T., Sekine N., Iijima M., Ohya S. Increase in susceptibility of Pseudomonas aeruginosa to carbapenem antibiotics in low-amino acid media. Antimicrob. Agents Chemother. 1991, 35:529-532.
12. Fukuoka T., Ohya S., Narita T., Katsuta M., Iijima M., Masuda N., Yasuda H., Trias J., Nikaido H. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob. Agents Chemother. 1993, 37:322-327.
13. Hammami S., Ghozzi R., Burghoffer B., Arlet G., Redjeb S. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital. Pathol. Biol. 2009, 57:530-535.
14. Hoban D.J., Biedenbach D.J., Mutnick A.H., Jones R.N. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY antimicrobial surveillance study (2000). Diagn. Microbiol. Infect. Dis. 2003, 45:279-285.
15. Hocquet D., Plésiat P., Dehecq B., Mariotte P., Talon D., Bertrand X. Nationwide investigation of extended spectrum beta lactamase, metallo-beta-lactamases, and extended spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeurginosa strains in France. Antimicrob. Agents Chemother. 2010, 54:3513-3515.
16. Huang H., Jeanteur D., Pattus F., Hancock R.E.W. Membrane topology and site specific mutagenesis of Pseudomonas aeruginosa porin OprD. Mol. Microbiol. 1995, 16:931-941.
17. Huang H., Hancock R.W. The role of specific surface loop regions in determining the function of the imipenem-specific pore protein OprD of Pseudomonas aeruginosa. J. Bacteriol. 1996, 178:3085-3090.
18. Keen E.F., Robinson B.J., Hospenthal D.R., Aldous W.K., Wolf S.E., Chung K.K., Murray C.K. Incidence and bacteriology of burn infections at a military burn center. Burns 2010, 36:461-468.
19. Koh T.H., Khoo C.T., Tan T.T., Arshad M.A., Ang L.P., Lau L.J., Hsu L.Y., Ooi E.E. Multilocus sequence types of carbapenem-resistant Pseudomonas aeruginosa in Singapore carrying metallo-beta-lactamase genes, including the novel bla(IMP-26) gene. J. Clin. Microbiol. 2010, 48:2563-2564.
20. Köhler T., Michéa-Hamzehpour M., Henze U., Gotoh N., Curty L.K., Pechère J.C. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol. Microbiol. 1997, 23:345-354.
21. Köhler T., Michéa-Hamzehpour M., Epp S.F., Pechère J.C. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. 1999, 43:424-427.
22. Köhler T., Epp S.F., Curty L.K., Pechère J.C. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J. Bacteriol. 1999, 181:6300-6305.
23. Kwon D.H., Lu C.D. Polyamine effects on antibiotic susceptibility in bacteria. Antimicrob. Agents Chemother. 2007, 51:2070-2077.
24. Lascols C., Legrand P., Mérens A., Leclercq R., Armand-Lefevre L., Drugeon H.B., Kitzis M.D., Muller-Serieys C., Reverdy M.E., Roussel-Delvannez M., Moubareck C., Lemire A., Miara A., Gjoklaj M., Soussy C.J. In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 30:475-482.
25. Lautenbach E., Synnestvedt M., Weiner M.G., Bilker W.B., Vo L., Schein J., Kim M. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 2010, 31:47-53.
26. Lister P.D., Wolter D.J. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin. Infect. Dis. 2005, 40:S105-S114.
27. Lister P.D., Wolter D.J., Wickman P.A., Reisbig M.D. Levofloxacin/imipenem prevents the emergences of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs. J. Antimicrob. Chemother. 2006, 57:999-1003.
28. Livermore D.M., Mushtaq S., Ge Y., Warner M. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int. J. Antimicrob. Agents 2009, 34:402-406.
29. Louie A., Bied A., Fregeau C., van Scoy B., Brown D., Liu W., Bush K., Queenan A.M., Morrow B., Khashab M., Kahn J.B., Nicholson S., Kulawy R., Drusano G.L. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob. Agents Chemother. 2010, 54:2638-2645.
30. Lynch M.J., Drusano G.L., Mobley H.L.T. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1987, 31:1892-1896.
31. Moya B., Zamorano L., Juan C., Pérez J.L., Ge Y., Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 2010, 54:1213-1217.
32. Muller C., Plésiat P., Jeannot K. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and beta-lactams in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2011, 55:1211-1221.
33. Muramatsu H., Horii T., Morita M., Hashimoto H., Kanno T., Maekawa M. Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates. Int. J. Med. Microbiol. 2003, 293:191-197.
34. Mushtaq S., Ge Y., Livermore D.M. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 2004, 48:3086-3092.
35. Naenna P., Noisumdaeng P., Pongpech P., Tribuddharat C. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates. Southeast Asian J. Trop. Med. Public Health 2010, 41:614-624.
36. National Nosocomial Infections Surveillance (NNIS) System National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 2004, 32:470-485.
37. Ochs M.M., Lu C.D., Hancock R.E.W., Abdelal A.T. Amino acid-mediated induction of the basic amino acid-specific outer membrane porin OprD from Pseudomonas aeruginosa. J. Bacteriol. 1999, 181:5426-5432.
38. Ochs M.M., McCusker M.P., Bains M., Hancock R.E.W. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob. Agents Chemother. 1999, 43:1085-1090.
39. Ochs M.M., Bains M., Hancock R.E.W. Role of putative loops 2 and 3 in imipenem passage through the specific porin OprD of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2000, 44:1983-1985.
40. Oliver A., Canton R., Campo P., Baquero F., Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288:1251-1254.
41. Perron K., Caille O., Rossier C., van Delden C., Dumas J.L., Köhler T. CzcR-CzsS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J. Biol. Chem. 2004, 279:8761-8768.
42. Pirnay J.P., De Vos D., Mossialos D., Vanderkelen A., Cornelis P., Zizi M. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ. Microbiol. 2002, 4:872-882.
43. Quale J., Bratu S., Gupta J., Landman D. Interplay of efflux system, ampC and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 2006, 50:1633-1641.
44. Quinn J.P., Dudek E.J., DiVincenzo C.A., Lucks D.A., Lerner S.A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis. 1986, 154:289-294.
45. Quinn J.P., Darzins A., Miyashiro D., Ripp S., Miller R.V. Imipenem resistance in Pseudomonas aeruginosa PAO: mapping of the OprD2 gene. Antimicrob. Agents Chemother. 1991, 35:753-755.
46. Sakyo S., Tomita H., Tanimoto K., Fujimoto S., Ike Y. Potency of carbapenems for the prevention of carbapenem resistant mutants of Pseudomonas aeruginosa. J. Antibiot. 2006, 59:220-228.
47. Sánchez-Gómez S., Japelj B., Jerala R., Moriyón I., Fernández Alonso M.F., Leiva J., Blondelle S.E., Andrä J., Brandenburg K., Lohner K., Martínez de Tejada G.M. Structural features governing the activity of lactoferricin-derived peptides that act in synergy with antibiotics against Pseudomonas aeruginosa in vitro and in vivo. Antimicrob. Agents Chemother. 2011, 55:218-228.
48. Song W., Lee K.M., Kang H.J., Shin D.H., Kim D.K. Microbiologic aspects of predominant bacteria isolated from the burn patients in Korea. Burns 2001, 27:136-139.
49. Takeda S., Nakai T., Wakai Y., Ikeda F., Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2007, 51:826-830.
50. Tanimoto K., Tomita H., Fujimoto S., Okuzumi K., Ike Y. Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. Antimicrob. Agents Chemother. 2008, 52:3795-3800.
51. Thomas S.R., Ray A., Hodson M.E., Pitt T.L. Increased sputum amino acid concentration and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax 2000, 55:795-797.
52. Trias J., Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1990, 34:52-57.
53. Trias J., Nikaido H. Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. J. Biol. Chem. 1990, 265:15680-15684.
54. Wolter D.J., Acquazzino D., Goering R.V., Sammut P., Khalaf N., Hanson N.D. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from patient with cystic fibrosis in the absence of carbapenem therapy. Clin. Infect. Dis. 2008, 46:137-141.
55. Yoneyama H., Nakae T. Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1993, 37:2385-2390.
56. Yoneyama H., Yoshihara E., Nakae T. Nucleotide sequence of the protein D2 gene of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1992, 36:1791-1793.
57. Yoshihara E., Gotoh N., Nishino T., Nakae T. Protein D2 porin of the Pseudomonas aeruginosa outer membrane bears the protease activity. FEBS Lett. 1996, 394:179-182.
58. Yoshihara E., Yoneyama H., Ono T., Nakae T. Identification of the catalytic triad of the protein D2 portease in Pseudomonas aeruginosa. Biochem. Biophys. Res. Commun. 1998, 247:142-145.
59. Zhanel G.G., Wiebe R., Dilay L., Thomson K., Rubinstein E., Hoban D.J., Noreddin A.M., Karlowsky J.A. Comparative review of the carbapenems. Drugs 2007, 67:1027-1052.
60. Zilberberg M.D., Chen J., Mody S.H., Ramsey A.M., Shorr A.F. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm. Med. 2010, 10:45-55.